Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: A retrospective analysis

Diabetes, Obesity and Metabolism

Volumn 14, Issue 9, 2012, Pages 803-809

  Pantalone, K M ^a   Kattan, M W ^b   Yu, C ^b   Wells, B J ^b   Arrigain, S ^b   Jain, A ^b   Atreja, A ^b   Zimmerman, R S ^b  

^a Summa Western Reserve Hospital Physicians Inc   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antidiabetic drug; Diabetes complications; Metformin; Pharmacoepidemiology; Sulphonylureas

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; METFORMIN;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

EID: 84864349212     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01604.x     Document Type: Article

References (19)

1. Horsdal HT, Johnsen SP, Sondergaard F, et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study Diabetes Metab Res Rev 2009; 25: 515-522.
2. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study Diabetes Res Clin Pract 2009; 86: 247-253.
3. Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis Diabetes Care 2010; 33: 1224-1229.
4. Zeller M, Danchin N, Simon D, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction J Clin Endocrinol Metab 2010; 95: 4993-5002.
5. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study Eur Heart J 2011; 32: 1900-1908.
6. Andersson C, Gislason GH, Jorgensen CH, et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure Diabetes Res Clin Pract 2011; 94: 119-125.
7. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker Circulation 1994; 90: 700-705.
8. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide Eur Heart J 1999; 20: 439-446.
9. Flynn DM, Smith AH, Treadway JL, et al. The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits Cardiovasc Drugs Ther 2005; 19: 337-346.
10. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide Cardiovasc Drugs Ther 2004; 18: 113-119.
11. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin Diabetes Care 2007; 30: 389-394.
12. Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis Acta Diabetol 2009; 46: 145-154.
13. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 1998; 17: 2265-2281.
14. Hoenig JM, Heisey DM. The abuse of power: the pervasive fallacy of power calculations for data analysis Am Stat 2001; 55: 19-24.
15. Snee RD. Validation of regression models: methods and examples Technometrics 1977; 19: 415-428.
16. van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example J Clin Epidemiol 2006; 59: 1102-1109.
17. Schafer J. Multiple imputation: a primer Stat Methods Med Res 1999; 8: 3-15.
18. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009; 32: 193-203.
19. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 2009; 52: 17-30.